Soluble VE-cadherin and VE-cadherin Antibody in Sclerodermic Sclerosis

University Hospital, Grenoble85 enrolled

Overview

Ve-cadherin is expressed in endothelial cells. Systemic slerosis is a rare auto-immune disease with a endothelial dysfunction. This study is to evaluated the level of soluble VE-cadherin and VE-cadherin antibody in patients with systemic slerosis.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Masking

NONE

Enrollment

Conditions

Primary Raynaud Disease Systemic Sclerosis

Interventions

soluble Ve cadherinBIOLOGICAL

dosage of soluble VE cadherine in each arms

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * group 1: systemic sclerosis * group 2: raynaud primary disease

Locations (1)

Grenoble University Hospital

Grenoble, France

Outcomes

Primary Outcomes

Level of soluble Ve-cadherin and antibody VE-cadherin with ELISA TEST in Scleroderma group versus Primary Raynaud's Phenomenon

Level of human sVE and antibody VE-cadherin in blood will be determined by ELISA test in both groups Scleroderma and Primary Raynaud's Phenomenon. The methodology of dosage of sVE is based on the pattern:WO/2008/062314 The methodolody of the dosage of antibody VE-cadherin is based on the pattern WO/2012/136820 . Group Scleroderma (N=60) versus Primary Raynaud's Phenomenon (N=20). Shapiro test.

Time frame: At 30 days average

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.